Clinical Trials Directory

Trials / Conditions / Refractory Malignant Germ Cell Tumor

Refractory Malignant Germ Cell Tumor

11 registered clinical trials studyying Refractory Malignant Germ Cell Tumor — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
NCT04901702
St. Jude Children's Research HospitalPhase 1 / Phase 2
Active Not RecruitingSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating
NCT04320888
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter
NCT04284774
National Cancer Institute (NCI)Phase 2
Active Not RecruitingIvosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat
NCT04195555
National Cancer Institute (NCI)Phase 2
Active Not RecruitingUlixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi
NCT03698994
National Cancer Institute (NCI)Phase 2
CompletedPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly
NCT03526250
National Cancer Institute (NCI)Phase 2
Active Not RecruitingEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi
NCT03213652
National Cancer Institute (NCI)Phase 2
CompletedSamotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H
NCT03213678
National Cancer Institute (NCI)Phase 2
CompletedTazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or
NCT03213665
National Cancer Institute (NCI)Phase 2
Active Not RecruitingLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or
NCT03213704
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc
NCT03155620
National Cancer Institute (NCI)Phase 2